Relay Therapeutics (RLAY) director Mark Murcko receives 32,947-share option grant

Rhea-AI Filing Summary

Relay Therapeutics director Mark Murcko received a new stock option award. The grant covers 32,947 shares of common stock at an exercise price of $14.09 per share and expires on June 8, 2036.

According to the terms, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date. After this award, Murcko holds options for 32,947 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Murcko Mark

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,947	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,947 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 32,947 shares Exercise price: $14.09 per share Expiration date: June 8, 2036 +1 more

4 metrics

Option grant size 32,947 shares Stock Option (Right to Buy) granted to director Mark Murcko

Exercise price $14.09 per share Conversion or exercise price of the stock option

Expiration date June 8, 2036 Option term end date for the stock option grant

Post-grant option holdings 32,947 shares Total option shares held directly following the transaction

Key Terms

Stock Option (Right to Buy), conversion or exercise price, vests in full, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

conversion or exercise price financial

"conversion_or_exercise_price: 14.0900"

vests in full financial

"and vests in full on the earlier to occur of"

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders following the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murcko Mark

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.09	06/09/2026		A		32,947		(1)	06/08/2036	Common Stock	32,947	$0	32,947	D

Explanation of Responses:

1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Relay Therapeutics (RLAY) director Mark Murcko report in this Form 4?

Mark Murcko reported receiving a stock option award for 32,947 shares of Relay Therapeutics common stock. The option is a compensation-related grant, not an open-market purchase or sale, and represents his directly held option position following this transaction.

What are the key terms of Mark Murcko’s new stock option in Relay Therapeutics (RLAY)?

The option covers 32,947 shares of common stock at an exercise price of $14.09 per share and expires on June 8, 2036. These terms define how many shares he can buy, at what price, and for how long.

How does the vesting schedule work for Mark Murcko’s Relay Therapeutics (RLAY) option grant?

The option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders. Vesting determines when he can exercise the option to buy shares.

Did Mark Murcko buy or sell Relay Therapeutics (RLAY) shares in the market?

No market buy or sell occurred in this filing; Murcko received a grant of stock options as compensation. The Form 4 records an acquisition of derivative securities, not a cash transaction in the company’s common stock.

How many Relay Therapeutics (RLAY) option shares does Mark Murcko hold after this grant?

Following the transaction, Murcko holds stock options for 32,947 underlying shares of Relay Therapeutics common stock. This figure reflects his directly owned derivative position reported in the Form 4 after the new grant.